Dergiler / Türk Kardiyoloji Derneği Arşivi / 2011 / Cilt: 39 - Sayı: 4

Down sendromlu çocuklarda kardiyopulmoner baypas sonrası trombositopeni sıklığı

The incidence of thrombocytopenia after cardiopulmonary bypass in children with Down syndrome

Sayfa
283–291
Yayın Tarihi
2022-11-05
DOI
—
🏛️Bu makalenin bibliyografik verileri ve tam metin bağlantısı DergiPark üzerinden sağlanmıştır.
DergiPark Kaydı ↗
✨

Yapay Zeka Hızlı Bakış & Çıkarımlar

AI Insight
⚡ TL;DR(1 Cümlede Hızlı Çıkarım)

Ameliyat öncesinde ve ameliyat sonrası 1-7. günler arasında trombosit sayıları ölçüldü.

📌 3 Maddede Bu Makale

🎯
Amaç & Hipotez:Amaç: Doğumsal kalp hastalığı nedeniyle kardiyopulmoner baypas ile düzeltme ameliyatı yapılan Down sendromlu çocuk hastalarda trombositopeni sıklığı araştırıldı.
📊
Temel Bulgular & Veri:Çalışma planı: Doğumsal kalp hastalığı tanısıyla tam düzeltme ameliyatı yapılan 162 hasta (81 kız, 81 erkek; ort. yaş 26.1±39.5 ay) geriye dönük olarak değerlendirildi.
💡
Sonuç & Katkı:Ameliyat öncesinde ve ameliyat sonrası 1-7. günler arasında trombosit sayıları ölçüldü.
🔬Tür:Araştırma Makalesi
📍Kapsam:162 hasta
⚙️Değişkenler:Alan Parametreleri

Özet

Amaç: Doğumsal kalp hastalığı nedeniyle kardiyopulmoner baypas ile düzeltme ameliyatı yapılan Down sendromlu çocuk hastalarda trombositopeni sıklığı araştırıldı. Çalışma planı: Doğumsal kalp hastalığı tanısıyla tam düzeltme ameliyatı yapılan 162 hasta (81 kız, 81 erkek; ort. yaş 26.1±39.5 ay) geriye dönük olarak değerlendirildi. Bu hastalar Down sendromu olan (118 hasta) ve olmayan (44 hasta, kontrol) şeklinde iki grupta incelendi. Ameliyat öncesinde ve ameliyat sonrası 1-7. günler arasında trombosit sayıları ölçüldü. Trombosit sayısının

Abstract

Objectives: We investigated the incidence of thrombocytopenia in pediatric patients with Down syndrome following cardiac surgery for congenital heart disease.Study design: We retrospectively evaluated 162 patients (81 girls, 81 boys; mean age 26.1±39.5 months) who underwent total surgical correction for congenital heart disease. The patients were divided into two groups with respect to the presence (n=118) or absence (n=44, controls) of Down syndrome. Platelet counts were performed preoperatively and on days 1 to 7 after surgery and thrombocytopenia was defined as a platelet count of less than 100,000/mm3.Results: The incidence of thrombocytopenia was significantly higher in patients with Down syndrome compared to controls (61.9% vs. 34.1%, p=0.002). Severe thrombocytopenia was observed in 22% and 4.6% of cases with and without Down syndrome, respectively. Postoperative platelet counts showed sharp decreases in both groups, bottoming out on day 3 and with more significant decreases in patients with Down syndrome; they started to rise on day 4, but remained lower than baseline levels on day 7. The only significant differences between the two groups in preoperative and postoperative variables were higher incidences of reintubation (26.3% vs. 9.1%, p=0.003) and complications during intensive care (50.9% vs. 27.3%, p=0.007) in cases with Down syndrome. Comparison of patients with and without thrombocytopenia independent of Down syndrome yielded significant differences for thrombocytopenic patients with respect to age, operation age, the presence of cyanosis, type of surgery and operation time, aortic clamp and bypass times, lengths of intensive care and hospital stay, intubation and chest tube drainage times, and the incidence of postoperative complications (p

🔖

Bu Makaleye Atıf Yap

VARAN, B., MERCAN, Ş., TOKEL, K., KARAGÖL, B. S. (2022). Down sendromlu çocuklarda kardiyopulmoner baypas sonrası trombositopeni sıklığı. Türk Kardiyoloji Derneği Arşivi, Cilt: 39 - Sayı: 4, 283–291. https://ajindex.com/articles/633161

📄 Tam Metin PDF Okuyucu

📄

PDF görüntüleyici hazırlanıyor...

Kaynakça (14)

  1. Gorlin RJ, Cohen MM, Hennekam RC, editors. Trisomy 21 syndrome (Down syndrome). In: Syndromes of the head and neck. 4th ed. New York: Oxford Universty Press; 2001. p. 35-41
  2. Derbent M, Tokel K. Congenital heart defects in patients with Down syndrome. In: Malard JA, editor. Focus on Down syndrome research. New York: Nova Science Publishers; 2004. p. 83-6
  3. Kater AP, Prins MH, von Rosenstiel IA, Ottenkamp J, Peters M. Transient thrombocytopenia after cardiac surgery in infants with Down syndrome. J Pediatr Hematol Oncol 1999;21:170-1
  4. Polski JM, Galambos C, Gale GB, Dunphy CH, Evans HL, Batanian JR. Acute megakaryoblastic leukemia after transient myeloproliferative disorder with clonal karyotype evolution in a phenotypically normal neonate. J Pediatr Hematol Oncol 2002;24:50-4
  5. Shiozawa Y, Fujita H, Fujimura J, Suzuki K, Sato H, Saito M, et al. A fetal case of transient abnormal myelopoiesis with severe liver failure in Down syndrome: prognostic value of serum markers. Pediatr Hematol Oncol 2004;21:273-8
  6. Gamis AS. Acute myeloid leukemia and Down syndrome evolution of modern therapy-state of the art review. Pediatr Blood Cancer 2005;44:13-20
  7. Zipursky A. Transient leukaemia-a benign form of leukaemia in newborn infants with trisomy 21. Br J Haematol 2003;120:930-8
  8. Kuşkonmaz B, Çetin M. Down sendromunda AML. Katkı Pediatri Dergisi 2004;26:397
  9. Liu H, Fleming NW, Moore PG. Anticoagulation for patients with heparin-induced thrombocytopenia using recombinant hirudin during cardiopulmonary bypass. J Clin Anesth 2002; 14:452-5
  10. Warkentin TE, Greinacher A. Heparin-induced thrombocytopenia and cardiac surgery. Ann Thorac Surg 2003;76:2121-31
  11. Digilio MC, Marino B. Genetic predisposition to ventricular septal defect in Down syndrome. Hum Genet 2001; 109:463
  12. Thies WR, Breymann T, Matthies W, Crespo-Martinez E, Meyer H, Körfer R. Primary repair of complete atrioventricular septal defect in infancy. Eur J Cardiothorac Surg 1991;5:571-4
  13. Kashima I, Aeba R, Katougi T, Mitsumaru A, Tsutsumi K, Iino Y, et al. Effect of Down’s syndrome on perioperative and long-term prognosis after ventricular septal defect repair. Kyobu Geka 2000;53:946-9. [Abstract] 14. Nakamura M, Toombs CF, Duarte IG, Ronson RS, Schmarkey LS, Katzmark SL, et al. Recombinant human megakaryocyte growth and development factor attenuates postbypass thrombocytopenia. Ann Thorac Surg 1998; 66:1216-23
  14. Malec E, Mroczek T, Pajak J, Januszewska K, Zdebska E. Results